ReviewAging and disease2025
Progress in Disease-Modifying Therapies for Parkinson's Disease.
Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Activation of the Nrf2-ARE Signaling Pathway Mediates the Neuroprotective Effects of Exercise in a Mouse Model of Chronic Parkinson's Disease.International journal of molecular sciences · 2026Article
- Systematic discovery of disease-modifying targets by prediction from knowledge graph-based AI model and experimental validation: Parkinson's disease case.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a highly prevalent neurodegenerative disorder, and current therapeutic approaches fail to prevent the progressive loss of dopaminergic neurons. To date, no disease-modifying therapies (DMTs) have been approved for PD. Developing effective DMTs remains the foremost objective in PD research. Here, we review the rationale for α-synuclein, LRRK2, GBA1, the PINK1-Parkin axis, and GLP-1R as potential therapeutic targets for PD. Additionally, we summarize the functional alterations observed in cellular organelles, including mitochondria, lysosomes, and the endoplasmic reticulum, in the context of PD. We also highlight the progress in drug development targeting these therapeutic candidates and the associated organelles. Furthermore, we discuss the advancements in stem cell-based therapeutic strategies in the field of PD research. It is believed that deepening understanding of disease mechanisms, combined with the development of novel technologies, offers promising potential for more effective solutions to this debilitating condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.